# Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

> **NCT03090880** · PHASE3 · TERMINATED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 59 (actual)

## Conditions studied

- Venous Thromboembolism
- Lung Neoplasm

## Interventions

- **DRUG:** Tinzaparin Sodium

## Key facts

- **NCT ID:** NCT03090880
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-14
- **Primary completion:** 2021-08-18
- **Final completion:** 2021-08-18
- **Target enrollment:** 59 (ACTUAL)
- **Why stopped:** The rate of inclusion is too low to hope to reach the target of 800 patients. 59 patients were included, and their data will not meet the research objectives.

The sponsor has decided to prematurely stop inclusions on January 13, 2022.
- **Last updated:** 2022-11-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03090880

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03090880, "Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03090880. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*